UNIT PURCHASE AGREEMENTUnit Purchase Agreement • July 12th, 2023 • Marizyme, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJuly 12th, 2023 Company Industry JurisdictionThis Unit Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of July 10, 2023, by and among Marizyme, Inc., a Nevada corporation (the “Company”), and each investor identified on Appendix A hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”).
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • June 5th, 2023 • Marizyme, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledJune 5th, 2023 Company Industry JurisdictionThis Unit Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of May 30, 2023, by and among Marizyme, Inc., a Nevada corporation (the “Company”), and each investor identified on Appendix A hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”).
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • May 18th, 2023 • Marizyme, Inc. • Pharmaceutical preparations • Nevada
Contract Type FiledMay 18th, 2023 Company Industry JurisdictionThis Unit Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of May 12, 2023, by and among Marizyme, Inc., a Nevada corporation (the “Company”), and each investor identified on Appendix A hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”).
UNIT PURCHASE AGREEMENTUnit Purchase Agreement • December 27th, 2021 • Marizyme Inc • Pharmaceutical preparations • New York
Contract Type FiledDecember 27th, 2021 Company Industry JurisdictionThis Unit Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of December , 2021, by and among Marizyme, Inc., a Nevada corporation (the “Company”), and each investor identified on Appendix A hereto (each, including its successors and assigns, an “Investor” and collectively, the “Investors”).